Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage ...

Scientists at the Ruđer Bošković Institute (RBI) in Zagreb, Croatia, have discovered that the protein CENP-E, long believed ...

Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy ...

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

The hypothesis was generated by a 27-billion-parameter foundation model called Cell2Sentence-Scale 27B (C2S-Scale), developed ...

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab-dlle) was found to improve overall ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

The German biotech Tubulis said it had raised a $358 million Series C round, a sizable funding that will help it push its ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...